Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor

被引:245
作者
Claudel, T
Leibowitz, MD
Fiévet, C
Tailleux, A
Wagner, B
Repa, JJ
Torpier, G
Lobaccaro, JM
Paterniti, JR
Mangelsdorf, DJ
Heyman, RA
Auwerx, J
机构
[1] Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, France
[2] Inst Pasteur, Dept Atherosclerose, INSERM, U325, F-59019 Lille, France
[3] Ligand Pharmaceut Inc, San Diego, CA 92121 USA
[4] X Ceptor Therapeut, San Diego, CA 92121 USA
[5] Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA
关键词
D O I
10.1073/pnas.041609298
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
A common feature of many metabolic pathways is their control by retinoid X receptor (RXR) heterodimers. Dysregulation of such metabolic pathways can lead to the development of atherosclerosis, a disease influenced by both systemic and local factors. Here we analyzed the effects of activation of RXR and some of its heterodimers in apolipoprotein E -/- mice, a well established animal model of atherosclerosis. An RXR agonist drastically reduced the development of atherosclerosis. In addition, a ligand for the peroxisome proliferator-activated receptor (PPAR)gamma and a dual agonist of both PPAR alpha and PPAR gamma had moderate inhibitory effects. Both RXR and liver X receptor (LXR) agonists induced ATP-binding cassette protein 1 (ABC-1) expression and stimulated ABC-l-mediated cholesterol efflux from macrophages from wild-type, but not from LXR alpha and beta double -/-, mice. Hence, activation of ABC-1-mediated cholesterol efflux by the RXR/LXR heterodimer might contribute to the beneficial effects of rexinoids on atherosclerosis and warrant further evaluation of RXR/LXR agonists in prevention and treatment of atherosclerosis.
引用
收藏
页码:2610 / 2615
页数:6
相关论文
共 39 条
  • [1] CANTORNA MT, 1994, J IMMUNOL, V152, P1515
  • [2] Colville-Nash PR, 1998, J IMMUNOL, V161, P978
  • [3] Costet P, 2000, J BIOL CHEM, V275, P28240
  • [4] Metabolic effects of rexinoids: Tissue-specific regulation of lipoprotein lipase activity
    Davies, PJA
    Berry, SA
    Shipley, GL
    Eckel, RH
    Hennuyer, N
    Crombie, DL
    Ogilvie, KM
    Peinado-Onsurbe, J
    Fievet, C
    Leibowitz, MD
    Heyman, RA
    Auwerx, J
    [J]. MOLECULAR PHARMACOLOGY, 2001, 59 (02) : 170 - 176
  • [5] The PPAR alpha-leukotriene B-4 pathway to inflammation control
    Devchand, PR
    Keller, H
    Peters, JM
    Vazquez, M
    Gonzalez, FJ
    Wahli, W
    [J]. NATURE, 1996, 384 (6604) : 39 - 43
  • [6] INHIBITION OF NITRIC-OXIDE SYNTHESIS IN VASCULAR SMOOTH-MUSCLE BY RETINOIDS
    HIROKAWA, K
    OSHAUGHNESSY, KM
    RAMRAKHA, P
    WILKINS, MR
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1994, 113 (04) : 1448 - 1454
  • [7] PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
    Jiang, CY
    Ting, AT
    Seed, B
    [J]. NATURE, 1998, 391 (6662) : 82 - 86
  • [8] NONSTEROID NUCLEAR RECEPTORS - WHAT ARE GENETIC-STUDIES TELLING US ABOUT THEIR ROLE IN REAL-LIFE
    KASTNER, P
    MARK, M
    CHAMBON, P
    [J]. CELL, 1995, 83 (06) : 859 - 869
  • [9] Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse
    Kozarsky, KF
    Donahee, MH
    Glick, JM
    Krieger, M
    Rader, DJ
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (03) : 721 - 727
  • [10] Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels
    Kozarsky, KF
    Donahee, MH
    Rigotti, A
    Iqbal, SN
    Edelman, ER
    Krieger, M
    [J]. NATURE, 1997, 387 (6631) : 414 - 417